Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.4.0.3
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Revenues:    
Royalties $ 14,390 $ 10,287
Material sales 5,341 3,729
License fees, milestones and other revenues 9,917 586
Total revenues 29,648 14,602
Operating costs and expenses:    
Cost of sales [1] 955 1,074
Amortization of intangibles 2,524 594
Research and development 4,004 3,368
General and administrative 6,825 5,994
Lease exit and termination costs 244 223
Total operating costs and expenses 14,552 11,253
Income from operations 15,096 3,349
Other (expense) income:    
Interest expense, net (3,005) (2,973)
Increase in contingent liabilities (1,306) (3)
Equity in net losses from Viking Therapeutics (1,605) 0
Other, net 391 (447)
Total other (expense) income, net (5,525) (3,423)
Income (loss) before income taxes 9,571 (74)
Income tax expense (3,694) (15)
Income (loss) from operations 5,877 (89)
Gain on sale of Oncology Product Line before income taxes 1,139 0
Income tax expense on discontinued operations (408) 0
Income from discontinued operations 731 0
Net income including noncontrolling interests: 6,608 (89)
Less: Net loss attributable to noncontrolling interests 0 (843)
Net income $ 6,608 $ 754
Basic earnings per share data    
Income from continuing operations (in usd per share) $ 0.28 $ 0.04
Income from discontinued operations (in usd per share) 0.04 0.00
Net income (in usd per share) 0.32 0.04
Diluted earnings per share data    
Income from continuing operations (in usd per share) 0.26 0.04
Income from discontinued operations (in usd per share) 0.03 0.00
Net income (in usd per share) $ 0.30 $ 0.04
Shares used for computation (in thousands)    
Basic (in shares) 20,708,000 19,612,000
Diluted (in shares) 22,283,979 20,630,788
[1] Excludes amortization of intangibles.